Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. G Pugliese , F Pricci , G Romeo , F Pugliese , P Mené , S Giannini , B Cresci , G Galli , C M Rotella , H Vlassara and U Di Mario Department of Experimenta...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 46; no. 11; pp. 1881 - 1887 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Diabetes Association
01.11.1997
|
Online Access | Get full text |
Cover
Loading…
Abstract | Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated
mechanism.
G Pugliese ,
F Pricci ,
G Romeo ,
F Pugliese ,
P Mené ,
S Giannini ,
B Cresci ,
G Galli ,
C M Rotella ,
H Vlassara and
U Di Mario
Department of Experimental Medicine, 2nd Institute of Internal Medicine, La Sapienza University, Rome, Italy.
Abstract
Enhanced advanced glycosylation end product (AGE) formation has been shown to participate in the pathogenesis of diabetes-induced
glomerular injury by mediating the increased extracellular matrix (ECM) deposition and altered cell growth and turnover leading
to mesangial expansion. These effects could be exerted via an AGE-receptor-mediated upregulation of growth factors, such as
the IGFs and transforming growth factor-beta (TGF-beta). We tested this hypothesis in human and rat mesangial cells grown
on nonglycated or native bovine serum albumin (BSA), glycated BSA with AGE formation (BSA-AGE), or glycated BSA in which AGE
formation was prevented by the use of aminoguanidine (BSA-AM), in the presence or absence of an antibody, alpha-p60, directed
against the p60/OST protein named AGE-receptor 1 (AGE-R1), or normal control (pre-immune) serum. The mRNA and/or protein levels
of IGF-I, IGF-II, IGF receptors, IGF binding proteins (IGFBPs), TGF-beta1 and the ECM components fibronectin, laminin, and
collagen IV were measured, together with cell proliferation. Both human and rat mesangial cells grown on BSA-AGE showed increased
IGF-I and total and bioactive TGF-beta medium levels and enhanced IGF-I, IGF-II, and TGF-beta1 gene expression, compared with
cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and IGF-I receptor
transcripts were unchanged. Moreover, cells grown on BSA-AGE showed increased ECM protein and mRNA levels versus cells cultured
on BSA, whereas cell proliferation was unchanged in human mesangial cells and slightly reduced in rat mesangial cells. Growing
cells on BSA-AM did not affect any of the measured parameters. Co-incubation of BSA-AGE with anti-AGE-R1, but not with pre-immune
serum, prevented AGE-induced increases in IGF-I, TGF-beta1, and ECM production or gene expression; anti-AGE-R1 also reduced
growth factor and matrix synthesis in cells grown on BSA. These results demonstrate that mesangial IGF and TGF-beta1 synthesis
is upregulated by AGE-modified proteins through an AGE-receptor-mediated mechanism. The parallelism with increased ECM production
raises the speculation that the enhanced synthesis of these growth factors resulting from advanced nonenzymatic glycation
participates in the pathogenesis of hyperglycemia-induced mesangial expansion. |
---|---|
AbstractList | Abstract only Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. G Pugliese , F Pricci , G Romeo , F Pugliese , P Mené , S Giannini , B Cresci , G Galli , C M Rotella , H Vlassara and U Di Mario Department of Experimental Medicine, 2nd Institute of Internal Medicine, La Sapienza University, Rome, Italy. Abstract Enhanced advanced glycosylation end product (AGE) formation has been shown to participate in the pathogenesis of diabetes-induced glomerular injury by mediating the increased extracellular matrix (ECM) deposition and altered cell growth and turnover leading to mesangial expansion. These effects could be exerted via an AGE-receptor-mediated upregulation of growth factors, such as the IGFs and transforming growth factor-beta (TGF-beta). We tested this hypothesis in human and rat mesangial cells grown on nonglycated or native bovine serum albumin (BSA), glycated BSA with AGE formation (BSA-AGE), or glycated BSA in which AGE formation was prevented by the use of aminoguanidine (BSA-AM), in the presence or absence of an antibody, alpha-p60, directed against the p60/OST protein named AGE-receptor 1 (AGE-R1), or normal control (pre-immune) serum. The mRNA and/or protein levels of IGF-I, IGF-II, IGF receptors, IGF binding proteins (IGFBPs), TGF-beta1 and the ECM components fibronectin, laminin, and collagen IV were measured, together with cell proliferation. Both human and rat mesangial cells grown on BSA-AGE showed increased IGF-I and total and bioactive TGF-beta medium levels and enhanced IGF-I, IGF-II, and TGF-beta1 gene expression, compared with cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and IGF-I receptor transcripts were unchanged. Moreover, cells grown on BSA-AGE showed increased ECM protein and mRNA levels versus cells cultured on BSA, whereas cell proliferation was unchanged in human mesangial cells and slightly reduced in rat mesangial cells. Growing cells on BSA-AM did not affect any of the measured parameters. Co-incubation of BSA-AGE with anti-AGE-R1, but not with pre-immune serum, prevented AGE-induced increases in IGF-I, TGF-beta1, and ECM production or gene expression; anti-AGE-R1 also reduced growth factor and matrix synthesis in cells grown on BSA. These results demonstrate that mesangial IGF and TGF-beta1 synthesis is upregulated by AGE-modified proteins through an AGE-receptor-mediated mechanism. The parallelism with increased ECM production raises the speculation that the enhanced synthesis of these growth factors resulting from advanced nonenzymatic glycation participates in the pathogenesis of hyperglycemia-induced mesangial expansion. |
Author | U Di Mario H Vlassara F Pugliese S Giannini G Pugliese P Mené F Pricci G Romeo C M Rotella G Galli B Cresci |
Author_xml | – sequence: 1 givenname: G. surname: Pugliese fullname: Pugliese, G. – sequence: 2 givenname: F. surname: Pricci fullname: Pricci, F. – sequence: 3 givenname: G. surname: Romeo fullname: Romeo, G. – sequence: 4 givenname: F. surname: Pugliese fullname: Pugliese, F. – sequence: 5 givenname: P. surname: Mene fullname: Mene, P. – sequence: 6 givenname: S. surname: Giannini fullname: Giannini, S. – sequence: 7 givenname: B. surname: Cresci fullname: Cresci, B. – sequence: 8 givenname: G. surname: Galli fullname: Galli, G. – sequence: 9 givenname: C. M. surname: Rotella fullname: Rotella, C. M. – sequence: 10 givenname: H. surname: Vlassara fullname: Vlassara, H. – sequence: 11 givenname: U. surname: Di Mario fullname: Di Mario, U. |
BookMark | eNptkNtKw0AQhhep1Lb6BN7sA5g6m83xUoonKHhjwbsw2UySlZzY3Z6ewlc2pYo3MhfDwPf_MN-cTbq-I8ZuBSx9KeP7QmNOjuwyiJZCLEWSiAs2E6lMPenHHxM2AxC-J-I0vmJzaz8BIBpnyqapDCMIYMa-NoOhatug033H-5K3ZLGrNDa8Mv3e1bxE5XrDsSs4HZxBRU0z8oa36Iw-cHvsXE1WW54fORY77BQVvGqO6txJY3AwfbFVzvKdRo7ckKJhLPVaGn9wI96SqrHTtr1mlyU2lm5-9oJtnh7fVy_e-u35dfWw9pQUwnlBEKc5AvllIsIySoICFAjIwwQhShXEUCqClKQPURIrP8aQIPSj8fZlGSZyweS5V5neWkNlNhjdojlmArKT3ezXbhZEmRDZye6Yujunal3Ve23oj_oP_wZa-4Lx |
CitedBy_id | crossref_primary_10_1016_S0306_9877_02_00172_X crossref_primary_10_2337_diabetes_53_11_2921 crossref_primary_10_1007_s10157_010_0357_1 crossref_primary_10_1046_j_1365_2796_2002_00932_x crossref_primary_10_1016_j_exger_2008_04_004 crossref_primary_10_1002_prca_201200101 crossref_primary_10_1111_j_1745_7254_2007_00570_x crossref_primary_10_1016_j_metabol_2007_05_016 crossref_primary_10_1080_08035320600885846 crossref_primary_10_1016_j_exer_2005_10_005 crossref_primary_10_1053_ajkd_2001_27414 crossref_primary_10_1002_dmrr_227 crossref_primary_10_1053_j_ackd_2005_01_008 crossref_primary_10_1016_j_ejphar_2011_09_185 crossref_primary_10_1016_j_pharmthera_2005_10_008 crossref_primary_10_1016_j_diabres_2006_01_001 crossref_primary_10_1093_ndt_15_3_347 crossref_primary_10_1016_j_atherosclerosis_2004_11_004 crossref_primary_10_1016_j_mvr_2005_10_001 crossref_primary_10_2337_diabetes_53_1_166 crossref_primary_10_1016_j_patbio_2006_07_003 crossref_primary_10_2337_diabetes_52_10_2586 crossref_primary_10_1016_j_preteyeres_2004_10_003 crossref_primary_10_1093_ndt_16_2_215 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.2337/diabetes.46.11.1881 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X 0012-1797 |
EndPage | 1887 |
ExternalDocumentID | 10_2337_diabetes_46_11_1881 diabetes_46_11_1881 |
GroupedDBID | - 08R 0R 1AW 29F 3V. 53G 55 5GY 5RE 5RS 7RV 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 8GL 8R4 8R5 AAQQT AAWTL AAYEP AAYJJ ABFLS ABOCM ABPTK ABUWG ACGOD ACPRK ADBBV ADBIT AENEX AFFNX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS AZQEC BBAFP BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BPHCQ BVXVI CS3 DIK DU5 DWQXO EBS EX3 F5P FRP FYUFA GICCO GJ GNUQQ GUQSH GX1 H13 HCIFZ HZ IAG IAO IEA IHR INH INR IOF IPO J5H K9- KM L7B LK8 M0R M1P M2O M2P M2Q M5 M7P MBDVC MVM O9- OB3 OBH OVD P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q2X RHF RHI RPM S0X SJFOW SJN SV3 TDI VH1 WH7 WOW X7M XZ YQJ ZA5 ZGI ZXP ZY1 --- .55 .GJ .XZ 08P 0R~ 1CY 354 6PF AAYXX ACGFO AEGXH AERZD AFHIN AI. AIAGR AIZAD ALIPV CCPQU CITATION EMOBN HMCUK HZ~ ITC M5~ N4W NAPCQ OHH OK1 TEORI UKHRP VVN YFH YOC ~KM |
ID | FETCH-LOGICAL-c311t-4479ba0e2f815f684d0c010b58a069c070fce09e320687c27a5e052632023f583 |
ISSN | 0012-1797 |
IngestDate | Fri Aug 23 02:43:46 EDT 2024 Fri Jan 15 19:48:14 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c311t-4479ba0e2f815f684d0c010b58a069c070fce09e320687c27a5e052632023f583 |
PMID | 9356040 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_2337_diabetes_46_11_1881 highwire_diabetes_diabetes_46_11_1881 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 1900 |
PublicationDate | 1997-11-01 |
PublicationDateYYYYMMDD | 1997-11-01 |
PublicationDate_xml | – month: 11 year: 1997 text: 1997-11-01 day: 01 |
PublicationDecade | 1990 |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 1997 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
SSID | ssj0006060 |
Score | 1.9584367 |
Snippet | Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated
mechanism.
G Pugliese ,
F... Abstract only |
SourceID | crossref highwire |
SourceType | Aggregation Database Publisher |
StartPage | 1881 |
Title | Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism |
URI | http://diabetes.diabetesjournals.org/content/46/11/1881.abstract |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWrYS4IJ6ivOQDnJYsceLEzpFHqwqpVVV1pd6i2LGXQ_ehbYoof4IfxR9j_IjXLRGiXKLE64yymW9nxrMznxF6w6tMMcFJImVbJlSzNBFSVwlRXEsBDi631YSHR-XBjH45K85Go19R1dJlJ6byx2Bfyf9oFcZAr6ZL9haaDUJhAM5Bv3AEDcPxn3Q8W2_cVvI-6luoi2Y5NznwOayuu69-Nx37BwEY4U1j0vS27nRhmPm_G74CCAANJwlEoaEcYH5-5RJ5E2VZBCwn7MXkm-nfmoCFVGsQmtieExOvLpTpHu6pCH2g-znK6d7c7SfKPhxD-G54Kmx6fhpGwThLW2awH8ZOVguX1o2mRTf7ia1v6GO-kS-yySQzJKnO7aqBMW-nfarS45FEVpdwt-2L9-BwyYa8Q5ZbfoE-qT2lJTiM6fbmmIv7ho8MlYuwZjJi6l5ITUtYRNVGyB20k7GqKMZo5-Pe0fFJCAhgjeg6ofyXcuRXRsz7gWe5HiD1pNVR0HP6AN33qxX8wUHvIRqp5SN099DXYzxGP2ME4pXGAYHYIRA7BGJAIL6GQOwQiAMCsbjCPQJxQCAGBOIegRgQiBv8BwJxQOATNNvfO_10kPgtPhKZE9IllLJKNKnKNCeFLjltU5mSVBS8SctKgj_SUqWVyrO05ExmrCmUYSiC6yzXBc-fovFytVTPEIa4nui8pblQGk4lJ4b7UbdMtZRWgu2id_17rdeOyaX-izZ30dv-3W8_Hpj3_HZiX6B72x_BSzTuNpfqFYS1nXjtYfMb10CoRw |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Upregulation+of+mesangial+growth+factor+and+extracellular+matrix+synthesis+by+advanced+glycation+end+products+via+a+receptor-mediated+mechanism&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Pugliese%2C+G.&rft.au=Pricci%2C+F.&rft.au=Romeo%2C+G.&rft.au=Pugliese%2C+F.&rft.date=1997-11-01&rft.issn=0012-1797&rft.eissn=0012-1797&rft.volume=46&rft.issue=11&rft.spage=1881&rft.epage=1887&rft_id=info:doi/10.2337%2Fdiabetes.46.11.1881&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_diabetes_46_11_1881 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |